Ilya Pharma presents first in class wound healing treatment at US Defense Department’s MHSRS 2022 Conference in Florida
ILP100 accelerates wound healing in humans and suited for use in unconventional settings. The company is excited that the DoD have selected the project to participate at the annual medical partnering conference.
Uppsala, Sweden, September 12, 2022: Ilya Pharma (the Company), a clinical stage immunotherapy company presented results from a first in human trial using its novel ILP100-Topical drug candidate at the US Defense Department’s MHSRS Conference in Florida. In a major breakthrough, ILP100 uses transformed lactic acid bacteria to produce and release the human chemokine CXCL12 for local immune-regulation. This results in TGFb upregulation and accelerated wound healing and reduced scar volume as shown in the data presented at MHSRS from a trial in 36 healthy volunteers with experimentally induced wounds. As well as military applications, Ilya believes ILP100 with its low production costs and stability is ideal also for all ambulatory settings.
The trial was designed as adaptive, randomized, double-blind and placebo-controlled, containing ascending single- and multi-dosing. The results show that administration of repeated doses of ILP100 in acute wounds is safe and well tolerated. Independent assessments by 3 blinded independent validators indicate that ILP100-treated wounds were registered as healed on average 6 days faster and 11 days faster for the highest dose than control-treated wounds, and lead to more healed wounds at the end of the active phase of the study, in a possible dose-dependent manner. These results are well positioned compared to the only two pharmaceuticals currently approved for wound healing, for which1-2 day accelerated healing in acute wounds is considered as clinically meaningful
Ilya is currently developing a portfolio of three first-in-class immunotherapies for skin and mucosal diseases, including ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic ulcers and ILP100-Oral for patients with immune mediated enterocolitis resulting from cancer treatment with checkpoint inhibitors.
CEO and Co-Founder Evelina Vågesjö comments: “We are delighted by the interest shown at this conference. Our approach is attracting increasing interest because of its universal applicability together with the low cost of manufacture and excellent stability as demonstrated so far. We believe this could lead to collaboration projects for proof of concept in special indications relevant to the military.”
Link to poster: https://www.ilyapharma.se/news-list/ilya-pharma-presents-poster-at-us-military-health-system-research-symposium-in-florida-september-12/
Notes to editors.
About Ilya Pharma - Ilya Pharma is a clinical stage biopharma company, developing novel drug candidates from its proprietary technology platform to clinical proof of concept in relevant patient groups with identified unmet medical needs. The lead drug candidate ILP100 is also known as emilomogene sigulactibac as recommended by the WHO. www.ilyapharma.se
For more information, please contact:
Evelina Vågesjö, CEO Tel: +46 (0) 70 636 64 94
Email: evelina.vagesjo@ilyapharma.se
Media
RHApr - Richard Hayhurst Tel: +44 (0) 7711 821527
Email: richard@rhapr.eu
